Robert Woodward - Azenta Senior Regulatory
| AZTA Stock | USD 45.16 0.37 0.81% |
Executive
Robert Woodward is Senior Regulatory of Azenta Inc
| Address | 200 Summit Drive, Burlington, MA, United States, 01803 |
| Phone | 978 262 2626 |
| Web | https://www.azenta.com |
Azenta Management Efficiency
The company has return on total asset (ROA) of (0.0173) % which means that it has lost $0.0173 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0763) %, meaning that it created substantial loss on money invested by shareholders. Azenta's management efficiency ratios could be used to measure how well Azenta manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.0075. In addition to that, Return On Capital Employed is expected to decline to -0.03. At present, Azenta's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.8 B, whereas Non Currrent Assets Other are forecasted to decline to about 45.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Erik Anderson | Hologic | 42 | |
| Suraj Satpathy | Envista Holdings Corp | N/A | |
| Marry Skafidas | AptarGroup | N/A | |
| Niro Ramachandran | Akoya Biosciences | 49 | |
| Peter Dunne | Hologic | 68 | |
| Paul Grass | Akoya Biosciences | N/A | |
| Rajeev Varma | Haemonetics | N/A | |
| Karleen CPA | Hologic | 54 | |
| Jan MD | Haemonetics | N/A | |
| Nicholas Khadder | The Cooper Companies, | 50 | |
| Filippo Impieri | Envista Holdings Corp | N/A | |
| Kerri DiPietro | Haemonetics | N/A | |
| Nicholas JD | The Cooper Companies, | 50 | |
| Brandon Schnittker | Hologic | 40 | |
| Marna BronfenMoore | AngioDynamics | 57 | |
| Stephen Keller | Envista Holdings Corp | 50 | |
| Mary Skafidas | AptarGroup | N/A | |
| Sarah Comstock | Merit Medical Systems | N/A | |
| Scott Christensen | Hologic | N/A | |
| Eric Hammes | Envista Holdings Corp | 49 | |
| Saleem Cheeks | AngioDynamics | N/A | |
Management Performance
| Return On Equity | -0.0763 | ||||
| Return On Asset | -0.0173 |
Azenta Inc Leadership Team
Elected by the shareholders, the Azenta's board of directors comprises two types of representatives: Azenta inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Azenta. The board's role is to monitor Azenta's management team and ensure that shareholders' interests are well served. Azenta's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Azenta's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vandana Sriram, Corp Fin | ||
| Jason JD, General VP | ||
| Kimberly Crowley, VP Officer | ||
| Luc Provost, VP Systems | ||
| Robin Vacha, Senior Operations | ||
| Sara Silverman, Head Communications | ||
| John OBrien, Senior Development | ||
| Lindon Robertson, Ex CFO | ||
| Michael Paulo, VP Officer | ||
| Ginger Zhou, Senior Solutions | ||
| Olga Pirogova, Senior Officer | ||
| David Wang, Senior Solutions | ||
| Stephen Schwartz, President CEO | ||
| Jason Joseph, General VP | ||
| Lawrence Lin, Chief Officer | ||
| Herman Cueto, Executive CFO | ||
| Violetta Hughes, VP Officer | ||
| John Marotta, President CEO | ||
| Robert Woodward, Senior Regulatory | ||
| Andrea OHara, Strategic Sciences | ||
| Claribel Purcell, VP Sales |
Azenta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Azenta a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0763 | ||||
| Return On Asset | -0.0173 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 1.67 B | ||||
| Shares Outstanding | 45.57 M | ||||
| Shares Owned By Insiders | 2.74 % | ||||
| Shares Owned By Institutions | 97.60 % | ||||
| Number Of Shares Shorted | 4.34 M | ||||
| Price To Earning | 38.92 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Azenta Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Azenta's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Azenta Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Azenta Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Azenta Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Azenta. If investors know Azenta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Azenta listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 87.778 | Earnings Share (3.09) | Revenue Per Share 12.343 | Quarterly Revenue Growth (0.01) | Return On Assets (0.02) |
The market value of Azenta Inc is measured differently than its book value, which is the value of Azenta that is recorded on the company's balance sheet. Investors also form their own opinion of Azenta's value that differs from its market value or its book value, called intrinsic value, which is Azenta's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Azenta's market value can be influenced by many factors that don't directly affect Azenta's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Azenta's value and its price as these two are different measures arrived at by different means. Investors typically determine if Azenta is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Azenta's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.